[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369793-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369793-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","integrated-computational-and-preclinical-evaluation-of-novel-synthetic-pyrazole-pyrazoline-thiazole-derivative-for-breast-cancer-therapeutics","Integrated computational and preclinical evaluation of novel synthetic pyrazole pyrazoline thiazole derivative for breast cancer therapeutics","","Integrated computational and preclinical evaluation investigates 10 novel synthetic pyrazole–pyrazoline–thiazole derivatives as potential breast cancer therapeutics. Computational modeling is used to estimate ligand-binding affinities and pharmacokinetic properties, followed by in vitro cytotoxicity testing on the MCF-7 human breast cancer cell line. A preclinical model evaluates anticancer activity through cytokine measurements including TGF-β, TNF-α, and IL-6, alongside antioxidant effects via malondialdehyde (MDA). Rat studies track body weight, tumor metrics, inflammation, and histology, identifying compound 5E as the most effective candidate by reducing TNF-α, IL-6, MDA, and TGF-β.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/integrated-computational-and-preclinical-evaluation-of-novel-synthetic-pyrazole-pyrazoline-thiazole-derivative-for-breast-cancer-therapeutics/369793/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/integrated-computational-and-preclinical-evaluation-of-novel-synthetic-pyrazole-pyrazoline-thiazole-derivative-for-breast-cancer-therapeutics/369793.png","ImageObject",300,407,{"name":42,"@type":43},"McGucket","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What derivatives were evaluated in this study?","Question",{"text":63,"@type":64},"The study tested 10 new synthetic pyrazole–pyrazoline–thiazole derivative forms for breast cancer therapeutic potential.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the compounds first assessed before animal testing?",{"text":68,"@type":64},"Computational models estimated ligand-binding affinities and pharmacokinetic properties, and cytotoxicity was measured using the MCF-7 human breast cancer cell line.",{"name":70,"@type":61,"acceptedAnswer":71},"Which marker changes indicated the best antitumor activity?",{"text":72,"@type":64},"Compound 5E showed the best activity by decreasing TNF-α, IL-6, MDA, and TGF-β, alongside supportive tumor and inflammatory/histological findings in rats.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369793,1790248912,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nIntegrated computational and preclinical evaluation of novel synthetic pyrazole pyrazoline thiazole derivative for breast cancer therapeutics  \nRushikumar Shah1, Ronak Kamani2, Dipak Raval2, Kirit Patel2, Vaibhav Prajapati2, Ronak Prajapati2, Sanika Dongre3, Umang Shah3􀀍 & Alkeshkumar Patel3􀀍  \nBreast cancer is the uncontrolled growth of breast cells in the lobules or the inner lining of milk ducts due to dysfunction of regulatory genes. The drugs currently used in breast cancer treatment have severe limitations. The study aimed to test 10 new synthetic forms of pyrazole clubbed pyrazoline thiazole derivatives for their ability to kill tumor cells, reduce inflammation, fight free radicals, and other important factors linked to breast cancer. The study involved computational models to assess ligand-binding affinities and pharmacokinetic properties. Later, we evaluated cytotoxicity using a human breast cancer cell line, MCF-7. In a preclinical model, the levels of vital cytokines like Transforming Growth Factor-β (TGF-β), Tumor Necrosis Factor alpha (TNF-α), and Interleukin-6 were used to test the anticancer activity. The antioxidant activity is evaluated by malondialdehyde (MDA) levels. Changes in body weight, tumor weight and volume, inflammatory cytokine concentrations, and histology were among the measurements taken in rats. In result, we found compound 5E [5-(2-fluorophenoxy)-4-(3-(4-fluorophenyl)-1-(4-(4-fluorophenyl)thiazol-2-yl)-4,5-dihydro-1 H-pyrazol- 5-yl)-3-methyl-1-phenyl-1 H-pyrazole] has best antitumor activity by decreasing the levels ofTNF-α, IL-6, MDA, and TGF-β. It was observed that compound 5E contains potential in vitro and in vivo anticancer activity.  \nKeywords Breast cancer, EGFR receptor, Pyrazole, Pyrazoline, Thiazole, TGF-β  \nAbbreviations  \nAhR Aryl hydrocarbon Receptor ANOVA Analysis of variance  \nARRIVE Animal Research: Reporting of In Vivo Experiments  \nB.W. Body Weight  \nBRCA1 Breast CAncer gene 1  \nBRCA2 Breast CAncer gene 2  \nCADD Computer-Aided Drug Design  \nCBC Complete Blood Count  \nCCSEA Committee for Control and Supervision of Experiments on Animals CDK Cyclin-Dependent Kinase  \nCY1B1 Cytochrome P450 Family 1 Subfamily B Member 1  \nCYP1A1 Cytochrome P450 Family 1 Subfamily A Member 1 DC Disease Control  \nDMBA 7,12-dimethylbenz [a] anthracene DMSO Dimethyl sulfoxide  \nEGFR Epidermal Growth Factor Receptor  \nELISA Enzyme-Linked Immunosorbent Assay  \n1Torrent Research Center, Ahmedabad, Gujarat, India. 2Department of Chemistry, Sardar Patel University, Vallabh Vidyanagar, Gujarat, India. 3Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, Gujarat, India. 􀀍 email: [umangshah.ph@gmail.com](umangshah.ph@gmail.com); [alkeshpatel.ph@charusat.ac.in](alkeshpatel.ph@charusat.ac.in)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nFBS Fetal Bovine Serum  \ni.p. Intraperitoneal  \nIAEC Institutional Animal Ethics Committee  \nIDC Invasive Ductal Cancer  \nIL-6 Interleukin-6  \nM1 TAMs M1 Tumor-Associated Macrophages MCR Multicomponent Reaction  \nMDA Malondialdehyde  \nMTT 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide NC Normal Control  \nNCCS National Centre for Cell Science  \nNF-kB Nuclear factor kappa B  \nPAHs Polycyclic Aromatic Hydrocarbons  \nPUFA Polyunsaturated Fatty Acids  \nROS Reactive Oxygen Species  \nSD Sprague-Dawley  \nSEM Standard Error of Mean  \nSMAD Suppressor of Mothers against Decapentaplegic  \nSTD Standard  \nTBA Thiobarbituric acid  \nTCA Trichloroacetic acid  \nTCDD 2,3,7,8-tetrachlorodibenzo[p]dioxin  \nTDL Terminal Duct Lobule  \nTGF-β Transforming growth factor-β TH Test-high dose  \nTL Test-low dose  \nTME Tumor Microenvironment  \nTNF-α Tumour Necrosis Factor alpha  \nVEGF Vascular Endothelial Growth Factor  \nWBC White Blood Cell  \nBreast cancer has the fourth highest mortality rate of all cancers, and it is the leading cause of canc","cbCaid2pm2QDZsYo","https://ap.wps.com/l/cbCaid2pm2QDZsYo","pdf",3516502,22,"English","# Introduction\n## Breast cancer burden and current therapy limitations\n## Genetic susceptibility and environmental carcinogens\n## Mechanisms involving AhR and CYP enzymes\n# Methods\n## Computational ligand-binding and pharmacokinetic assessment\n## In vitro cytotoxicity in MCF-7 cells\n## Preclinical evaluation: cytokines and antioxidant markers\n## Animal study measurements and histology\n# Results and Discussion\n## Antitumor efficacy of compound 5E\n## Changes in TNF-α, IL-6, MDA, and TGF-β","[{\"question\":\"What derivatives were evaluated in this study?\",\"answer\":\"The study tested 10 new synthetic pyrazole–pyrazoline–thiazole derivative forms for breast cancer therapeutic potential.\"},{\"question\":\"How were the compounds first assessed before animal testing?\",\"answer\":\"Computational models estimated ligand-binding affinities and pharmacokinetic properties, and cytotoxicity was measured using the MCF-7 human breast cancer cell line.\"},{\"question\":\"Which marker changes indicated the best antitumor activity?\",\"answer\":\"Compound 5E showed the best activity by decreasing TNF-α, IL-6, MDA, and TGF-β, alongside supportive tumor and inflammatory/histological findings in rats.\"}]","Integrated computational and preclinical evaluation of novel synthetic pyrazole pyrazoline thiazole derivative for breast cancer therapeutics | PDF",1790184582,55,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9062fa8182537658374e2fd875b207af.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d549de4704e811946de52773348c9221.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ac2156cc36f0f19afabe92712aa0238.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47a61e48c5e00bb7ed1f3adb152ee281.webp",980,1287]